In another study, angiopep-2-decorated cationic lipid-poly (lactic-co-glycolic acid) (PLGA) NPs were designed for the dual delivery of gefitinib (an EGFR tyrosine kinase inhibitor) and golgi phosphoprotein 3 (GOLPH3) siRNAs that would act as an effective combinatorial for anti-glioblastoma therapy. The gene discussed is GOLPH3; the disease is glioblastoma.